NCT04861298View on ClinicalTrials.gov

Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early Mild Symptoms of COVID-19

NACompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

August 29, 2021

Study Completion Date

August 29, 2021

Conditions

COVID-19

Interventions

DRUG

standard of care for COVID-19 as per the hospital guidelines

Hospital standard of care treatment for COVID-19

DIETARY_SUPPLEMENT

Quercetin Phytosome (QP)

Daily dose of 600 mg of Quercetin for 1st week and then 400 mg for the 2nd week

Trial Locations (1)

54000

King Edward Medical University Teaching Hospital, Lahore

All Listed Sponsors

lead

King Edward Medical University

OTHER

NCT04861298 - Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early Mild Symptoms of COVID-19 | Biotech Hunter | Biotech Hunter